Carcinogenesis in inflammatory bowel disease

Digestive Diseases

Volumn 25, Issue 3, 2007, Pages 267-269

  Herszenyi, Laszlo ^a   Miheller, Pal ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Colitis associated colon carcinogenesis, molecular pathways; Colorectal cancer in IBD, incidence; Colorectal cancer in IBD, risk factors; Inflammatory bowel disease, carcinogenesis; Surveillance colonoscopy

Indexed keywords

APC PROTEIN; K RAS PROTEIN; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CAUSE OF DEATH; CHROMOSOMAL INSTABILITY; CLINICAL EFFECTIVENESS; COLON; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONFERENCE PAPER; CROHN DISEASE; DISEASE SEVERITY; DYSPLASIA; ENDOSCOPY; ENTERITIS; EPIGENETICS; FAMILY HISTORY; HUMAN; MALIGNANT TRANSFORMATION; MICROSATELLITE INSTABILITY; MOLECULAR DYNAMICS; ONSET AGE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTITIS; SURVIVAL TIME; ULCERATIVE COLITIS; ARTICLE; CELL TRANSFORMATION; COLORECTAL TUMOR; HEALTH SURVEY; INCIDENCE; PATHOLOGY; RISK FACTOR;

CELL TRANSFORMATION, NEOPLASTIC; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; COLORECTAL NEOPLASMS; CROHN DISEASE; HUMANS; INCIDENCE; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 35449002488     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103898     Document Type: Conference Paper

References (20)

1. Munkholm P: Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(suppl 2):1-5.
2. Itzkowitz S, Harpaz N: Diagnosis and management of dysplasia in patients with inflammatory bowel disease. Gastroenterology 2004;126:1634-1648.
3. Vagefi PA, Longo WE: Colorectal cancer in patients with inflammatory bowel disease. Clin Colorectal Cancer 2005;4:313-319.
4. Eaden JA, Abrams KR, Mayberry JF: The true risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gastroenterology 2001;48:526-535.
5. Carter MJ, Lobo AJ, Travis SP: Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(suppl 5):V1-V16.
6. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126: 451-459.
7. Krok KL, Lichtenstein GR: Colorectal cancer in inflammatory bowel disease. Curr Opin Gastroenterol 2004;20:43-48.
8. Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A: Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356-1362.
9. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54.
10. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmesiter AR, Tremaine WJ, Sandborn WJ: Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006;130:1941-1949.
11. Itzkowitz S: Colon carcinogenesis in inflammatory bowel disease. J Clin Gastroenterol 2003;36(suppl 1):S70-S74.
12. Harpaz N: Adenoma-like dysplastic polyps in inflammatory bowel disease. Pathol Case Rev 2004;9:135-141.
13. Thomas T, Nair P, Dronfield MW, Mayberry JF: Management of low- and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol 2005;17:1317-1324.
14. Schulmann K, Mori Y, Croog V, Yin J, Olaru A, Sterian A, Sato F, Wang S, Xu Y, Deacu E, Berki AT, Hamilton JP, Kan T, Abraham JM, Schmiegel W, Harpaz N, Meltzer SJ: Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology 2005;129:74-85.
15. Itzkowitz SH, Present DH: Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314-321.
16. Rubin DT, Kavitt RT: Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am 2006;35:581-604.
17. Collins PD, Mpofu C, Watson AJ, Rhodes JM: Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;2:CD000279.
18. Geboes K: What are the important endoscopic lesions for detection of dysplasia in inflammatory bowel disease? Aliment Pharmacol Ther 2006;24(suppl 3):50-55.
19. Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Koprowicz KM, Bronner MP, Brentnall TA: DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 2003;162:665-672.
20. Selaru FM, Xu Y, Yin J, Zou T, Liu TC, Mori Y, Abraham JM, Sato F, Wang S, Twigg C, Olaru A, Shustova V, Leytin A, Hytiroglou P, Shibata D, Harpaz N, Meltzer SJ: Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterology 2002;122:606-613.